Friday 11 January 2013, by
SLC45A3 show a weaker expression in cancer as compared to benign tissue, which was pronounced in cases with SLC45A3-ERG fusion.
SLC45A3 down regulation is significantly associated with shorter PSA-free survival times.
In contrast, TMPRSS2 is neither differentially expressed nor do it show a correlation between protein expression and rearrangement status.
The expression of SLC45A3 protein is down regulated through SLC45A3-ERG fusion in prostate cancer.
These cases may represent a distinct molecular subclass of ERG rearranged prostate cancer with distinct clinical features.
Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course. Perner S, Rupp NJ, Braun M, Rubin MA, Moch H, Dietel M, Wernert N, Jung K, Stephan C, Kristiansen G. Int J Cancer. 2012 Jul 23. PMID: 22821757